Published : 27 May 2025

---

We are pleased to announce that Aagami has been appointed by a US based Biopharma to help them raise investments.

 

About the Client: 

Ann Arbor based client offers a compelling and novel Mechanism of Action using synthetic HDL to exploit the method which cancel cells use to grow. Instead of receiving normal HDL with cholesterol needed for growth, like a Trojan Horse, their smart targeted drug delivery platform tricks the cancer cell and deliver the proven, approved chemo drug instead.

·       Proof of Concept Completed

·       Can Treat Many Types of Cancer -  Over 60% of Known Chemotherapeutics Can Be Supported

·       High Tolerability with Increased Efficacy

·       Longer Patient Survival

·       Improved Quality of Life

·       Addresses a multi-billion dollar market

 

Their lead asset incorporates Paclitaxel in their smart drug delivery platform

o   Animal studies in dogs and rats demonstrate virtually no side effects at dosage exposures 100X + the standard of care (Taxol® and Abraxane®).

o   Widens the Therapeutic Window - Larger dosages for longer periods of time

o   All this while maintaining or improving the efficacy and supressing tumors.

o   Superior stability

o   Streamlined 505(b)(2) pathway

o   Efficient manufacturing plan - Saves as much as 9 months development timeline.

o   Proven Team of Bio Pharma Veterans with Exceptional Experience

o   Worldwide Broad Patent Coverage in all 12 Major Markets

o   On schedule to start clinical trials in 2025, First patient dosed late Q2/ early Q3

 

The US FDA has agreed to ALL key requests and MORE. Will result in not only $ millions in development cost savings, but also $ Billions in future revenue from earlier market entry.

Aagami are excited to support their Series A funding which is already has several commitments. If you are interested to know more about this investment opportunity, please contact us and we will send you a non-confidential deck for review.